Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 10/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.37 |
| ▸ | FLT4 | P35916 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989748 | 0.82 | MAPT (0.54) | MAPK9MAPK10KDR | |
| SCHEMBL4833774 | 0.80 | KDR (0.43) | MAPK9MAPK10KDRFLT1FLT4 | |
| SCHEMBL25442750 | 0.70 | MAPK9 (0.56) | MAPK9MAPK10KDRFLT1FLT4 | |
| SCHEMBL28354375 | 0.70 | KDR (0.54) | MAPK9MAPK10KDRFLT1FLT4 | |
| SCHEMBL989236 | 0.70 | MAPK14 (0.46) | MAPK9MAPK10KDRFLT1FLT4 | |
| SCHEMBL23903288 | 0.70 | MAPK9 (0.53) | MAPK9MAPK10KDRFLT1FLT4 | |
| SCHEMBL17743635 | 0.70 | MAPK9 (0.51) | MAPK9MAPK10KDRFLT1FLT4 | |
| SCHEMBL23903552 | 0.69 | MAPK9 (0.51) | MAPK9MAPK10KDRFLT1FLT4 | |
| SCHEMBL23903328 | 0.69 | MAPK9 (0.51) | MAPK9MAPK10KDRFLT1FLT4 | |
| SCHEMBL25442243 | 0.69 | MAPK9 (0.51) | MAPK9MAPK10KDRFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | MAPK9 140/4885MAPK10 318/4885KDR 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.